Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
1(9%)
Results Posted
100%(9 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
4
36%
Ph phase_3
5
45%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
5(45.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
90.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 24 (36.4%)
Phase 35 (45.5%)

Trials by Status

completed982%
recruiting19%
terminated19%

Recent Activity

1 active trials
Showing 5 of 11
recruitingphase_3

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

NCT05918861
completedphase_2

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

NCT04676867
completedphase_3

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

NCT02525939
terminatedphase_3

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

NCT01059682
completedphase_2

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

NCT00353522
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05918861Phase 3

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Recruiting
NCT04676867Phase 2

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

Completed
NCT02525939Phase 3

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Completed
NCT01059682Phase 3

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

Terminated
NCT00353522Phase 2

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Completed
NCT00697203Phase 2

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Completed
NCT00655538Phase 2

A Study Assessing the Effect of RO4607381 on Vascular Function in Patients With Coronary Heart Disease (CHD) or CHD-Risk Equivalent Patients

Completed
NCT01476267Phase 1

A Study of the Metabolic Profile of Dalcetrapib in Healthy Volunteers

Completed
NCT01363999Phase 1

A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers

Completed
NCT01323153Phase 3

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Completed
NCT01516541Phase 3

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11